298 reports of this reaction
1.8% of all BLINATUMOMAB reports
#10 most reported adverse reaction
NEUTROPENIA is the #10 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 298 FDA adverse event reports linking BLINATUMOMAB to NEUTROPENIA. This represents approximately 1.8% of all 16,815 adverse event reports for this drug.
Patients taking BLINATUMOMAB who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is a less commonly reported adverse event for BLINATUMOMAB, but still significant enough to appear in the safety profile.
In addition to neutropenia, the following adverse reactions have been reported for BLINATUMOMAB:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 298 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 1.8% of all adverse event reports for BLINATUMOMAB, making it a notable side effect.
If you experience neutropenia while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.